Daniel Albertson
No Rating Available
(Learn About Our Rating System)

Daniel Albertson, MD

Languages spoken: English

Dr. Albertson is a professor of pathology at the University of Utah School of Medicine and currently serves as the Division Chief for Anatomic Pathology and Molecular Oncology. He previously served as the Section Head for Surgical Pathology as well as the head of Genitourinary Pathology.

He received his MD from the University of Nebraska and completed his residency in anatomic and clinical pathology at Creighton University, followed by a surgical pathology fellowship at the University of Utah. While at Creighton, Dr. Albertson served as the chief resident for two years and received the Hal Lankford Pathology Resident Award.

He is a member of the United States and Canadian Academy of Pathology and the College of American Pathologists.

Dr. Albertson’s special research interests include genitourinary, gynecologic and solid tumor pathology.

Specialties

  • Pathology, Anatomical

Board Certification

American Board of Pathology (Anatomic & Clinical)
National Board of Medical Examiners

Dr. Albertson is a professor of pathology at the University of Utah School of Medicine and currently serves as the Division Chief for Anatomic Pathology and Molecular Oncology. He previously served as the Section Head for Surgical Pathology as well as the head of Genitourinary Pathology.

He received his MD from the University of Nebraska and completed his residency in anatomic and clinical pathology at Creighton University, followed by a surgical pathology fellowship at the University of Utah. While at Creighton, Dr. Albertson served as the chief resident for two years and received the Hal Lankford Pathology Resident Award.

He is a member of the United States and Canadian Academy of Pathology and the College of American Pathologists.

Dr. Albertson’s special research interests include genitourinary, gynecologic and solid tumor pathology.

Board Certification and Academic Information

Academic Departments Pathology -Professor (Clinical)
Board Certification
American Board of Pathology (Anatomic & Clinical)
National Board of Medical Examiners

Education history

Undergraduate Summa Cum Lade - Xavier University, Natural Sciences B.S.
Professional Medical Medicine - University of Nebraska College of Medicine M.D.
Residency Residency Program (Anatomic & Clinical Pathology) - Creighton University Medical Center, Department of Pathology Resident
Chief Resident Creighton University Medical Center Chief Resident
Fellowship Surgical Pathology - University of Utah Department of Pathology/ARUP Laboratories Fellow

Selected Publications

Journal Article

  1. Beech C, Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim J, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2025). Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ Hybridization. Applied immunohistochemistry & molecular morphology, 33(2), 91-102.
  2. Ferrero A, Ghelichkhan E, Manoochehri H, Ho MM, Albertson DJ, Brintz BJ, Tasdizen T, Whitaker RT, Knudsen B (2024). HistoEM: A Pathologist-Guided and Explainable Workflow Using Histogram Embedding for Gland Classification. Modern pathology, 37(4), 100447.
  3. Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seasor T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, Agarwal N, Swami U, Sirohi (2024). Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. Human pathology, 144, 28-33.
  4. Luo MX, Lyle A, Bennett P, Albertson D, Sirohi D, Maughan BL, McMurtry V, Mahlow (2024). Artificial intelligence chatbot vs pathology faculty and residents: Real-world clinical questions from a genitourinary treatment planning conference. American journal of clinical pathology, 162(6), 541-3.
  5. Light N, Layeghifard M, Attery A, Subasri V, Zatzman M, Anderson ND, Hatkar R, Blay S, Chen D, Novokmet A, Fuligni F, Tran J, de Borja R, Agarwal H, Waldman L, Abegglen LM, Albertson D, Finlay JL, Hansford JR, Behjati S, Villani A, Gerstung M, Alexandrov LB, Somers GR, Schiffman JD, Rotter V, Malkin D, Shlien (2023). Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nature communications, 14(1), 77.
  6. Wilcock DM, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Cleary AS, Lomo L, Ruano AL, Gering M, Bradshaw D, Maughan M, Tran P, Burlingame J, Davis R, Affolter K, Albertson DJ, Adelhardt P, Kim JT, Coleman JF, Deftereos G, Gulbahce EH, Sirohi (2023). Quantitative Imaging Analysis Fluorescence In Situ Hybridization Validation for Clinical HER2 Testing in Breast Cancer. Archives of pathology & laboratory medicine,
  7. Wilcock D, Sirohi D, Albertson D, Cleary AS, Coleman JF, Jedrzkiewicz J, Mahlow J, Ruano AL, Gulbahce H (2023). Clinicopathologic Features of Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists Fluorescence In Situ Hybridization Group 3 (Human Epidermal Growth Factor Receptor 2 Chromosome 17 Centromere Ratio <2.0 and Average Human Epidermal Growth Factor Receptor 2 Copy Number ¿6.0) Breast Cancers. Archives of pathology & laboratory medicine, 148(8), 890-897.
  8. Tward J, Lenz L, Flake DD II,, Rajamani S, Yonover P, Olsson C, Kapoor DA, Mantz C, Liauw SL, Antic T, Fabrizio M, Salzstein D, Shore N, Albertson D, Henderson J, Lee SP, Gay HA, Michalski J, Hung A, Raben D, Garraway I, Lewis MS, Nguyen PL, Marshall DT, Brawer MK, Stone S, Cohen (2022). The Clinical Cell-Cycle Risk (CCR) Score Is Associated With Metastasis After Radiation Therapy and Provides Guidance on When to Forgo Combined Androgen Deprivation Therapy With Dose-Escalated Radiation. International journal of radiation oncology, biology, physics, 113(1), 66-76.
  9. Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen (2022). Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Clinical genitourinary cancer, 20(3), e233-e243.
  10. Wilcock DM, McMurtry V, Coleman JF, Kim JT, Khalili P, Deftereos G, Albertson D, Gulbahce EH, Liu T, Sirohi (2022). Histopathological Correlation of Chromosome 12 Polysomy by Fluorescence in Situ Hybridization in Adipocytic Neoplasms. International journal of surgical pathology, 30(7), 734-742.
  11. Ward M, Albertson D, Furtado LV, Deftereos (2022). PD-L1 Tumor Cell Expression in Upper Tract Urothelial Carcinomas is Associated With Higher Pathologic Stage. Applied immunohistochemistry & molecular morphology, 30(1), 56-61.
  12. Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, O'Shea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma (2019). Histone Deacetylase Inhibition Has Targeted Clinical Benefit in ARID1A-Mutated Advanced Urothelial Carcinoma. Molecular cancer therapeutics, 18(1), 185-195.
  13. Tward JD, Poppe MM, Hitchcock YJ, O'Neil B, Albertson DJ, Shrieve D (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer medicine, 7(12), 6030-6039.
  14. Monument MJ, Grossmann AH, Baker CC, Randall RL, Liu T, Albertson D (2015). Molecular Confirmation of Ewing Sarcoma in an 85-Year-Old Woman. International journal of surgical pathology, 23(6), 500-4.
  15. Witt BL, Albertson DJ, Coppin MG, Horrocks CF, Post M, Gulbahce H (2015). Use of in situ hybridization for HPV in head and neck tumors: experience from a national reference laboratory. Head and neck pathology, 9(1), 60-4.
  16. Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner S (2014). A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Neoplasia (New York, N.Y.), 16(5), 403-12.